Therapeutic Proteins Market Report 2026

The therapeutic proteins market size has grown rapidly in recent years. It will grow from $177.3 billion in 2025 to $200.43 billion in 2026 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to successful commercialization of insulin therapies, rising prevalence of chronic diseases, strong clinical efficacy of protein drugs, growth of biotechnology research, increased regulatory approvals.

The therapeutic proteins market size is expected to see rapid growth in the next few years. It will grow to $332.37 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to expanding oncology and immunology pipelines, increasing biologics approvals, rising investment in biopharmaceutical R&D, growing adoption of biosimilars, improved manufacturing scalability. Major trends in the forecast period include expansion of recombinant protein therapies, rising demand for targeted biologics, growth of personalized protein medicines, increased adoption of long acting proteins, advancement in protein expression systems.

The increasing prevalence of chronic diseases, including diabetes, is expected to fuel the growth of the therapeutic protein market in the years ahead. Chronic diseases are conditions that generally last for one year or more, limit daily activities, require continuous medical attention, or both. Diabetes is a long-term disorder in which the body either fails to produce adequate insulin or cannot efficiently utilize the insulin it produces. Protein-based therapies, such as insulin and GLP-1 receptor agonists, are widely used in diabetes management to help control blood glucose levels. These treatments promote insulin secretion in response to elevated blood sugar levels while simultaneously reducing glucagon secretion, a hormone that raises blood glucose levels. For instance, in May 2024, according to the British Diabetic Association (Diabetes UK), a UK-based charity supporting patients, healthcare professionals, and research, around 4.4 million people in the UK were living with a diagnosed form of diabetes during 2022-23. Among these individuals, approximately 8% had type 1 diabetes, nearly 90% had type 2 diabetes, and the remaining 2% were affected by other less common forms. As a result, the growing burden of chronic diseases such as diabetes is driving the expansion of the therapeutic protein market.

Major companies operating in the therapeutic protein market are also focusing on launching advanced media systems to meet rising demand and enhance their competitive position. Media systems for therapeutic proteins are specialized manufacturing platforms developed to optimize the production of therapeutic monoclonal antibodies and other protein-based drugs. For example, in July 2023, Lonza Group AG, a Switzerland-based pharmaceutical manufacturing company, introduced the TheraPRO CHO (Chinese Hamster Ovary) Media System, a novel cell culture platform designed to improve productivity and product quality in therapeutic protein manufacturing. This two-part, chemically defined production system offers ease of use, simplified media preparation, complete scalability, and is supported by technical experts who provide comprehensive troubleshooting assistance.

In March 2024, Merck & Co. Inc., a US-based pharmaceutical company, acquired Harpoon Therapeutics in a deal valued at $680 million. This acquisition strengthens Merck’s oncology pipeline by adding a portfolio of innovative T-cell engagers, including HPN328 (MK-6070). This investigational therapy targets delta-like ligand 3 (DLL3) to enhance T-cell engagement against cancer. Harpoon Therapeutics is a US-based company specializing in therapeutic proteins.

Major companies operating in the therapeutic proteins market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi S.A, Bristol Myers Squibb Co., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk A/S, Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring LLC, Chugai Pharmaceutical Co. Ltd., Biogen Inc., Kyowa Kirin Co. Ltd., Oramed Pharmaceuticals Inc., Sandoz International GmbH, Hualan Biological Engineering Inc., Genentech Inc., ProBiogen AG, Diasome Pharmaceuticals Inc., Generex Biotechnology Corp., GeneScience Pharmaceuticals Co. Ltd.

North America was the largest region in the therapeutic proteins market in 2025. The regions covered in the therapeutic proteins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the therapeutic proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the therapeutic proteins market by increasing costs associated with imported biologic raw materials, reagents, and bioprocessing equipment. This has placed cost pressure on insulin, fusion proteins, and erythropoietin segments, particularly in regions dependent on international supply chains such as Asia Pacific and Europe. Manufacturing timelines have also been affected due to higher import compliance requirements. At the same time, tariffs are encouraging localized biomanufacturing investments and strengthening domestic biologics production capabilities.

The therapeutic proteins market research report is one of a series of new reports that provides therapeutic proteins market statistics, including therapeutic proteins industry global market size, regional shares, competitors with a therapeutic proteins market share, detailed therapeutic proteins market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic proteins industry. This therapeutic proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Therapeutic proteins are pharmaceutical products that are genetically engineered forms of naturally occurring human proteins. These highly potent and fast-acting medicines are produced in laboratory environments for pharmaceutical applications. Therapeutic proteins have played a major role in transforming disease management because of their high in vivo effectiveness.

The main product types in the therapeutic proteins market include insulin, fusion proteins, erythropoietin, interferon, human growth hormone, and follicle-stimulating hormone. Insulin is a peptide hormone secreted by the beta cells of the pancreas and functions as the body’s primary anabolic hormone. It regulates fat, carbohydrate, and protein metabolism by promoting glucose uptake from the bloodstream into fat, liver, and skeletal muscle cells. The different functions include enzymatic and regulatory activity, targeted activity, vaccines, and protein diagnostics, and these products are applied in areas such as metabolic disorders, immunologic disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, and others.

The therapeutic proteins market consists of sales of antibody-based drugs, FC fusion proteins, and anticoagulants. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.